LAMBERTUCCI, Catia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.653
EU - Europa 7.036
AS - Asia 5.370
SA - Sud America 719
Continente sconosciuto - Info sul continente non disponibili 442
AF - Africa 236
OC - Oceania 15
Totale 28.471
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.175
CN - Cina 2.175
SG - Singapore 1.644
RU - Federazione Russa 1.535
PL - Polonia 1.311
IT - Italia 1.227
DE - Germania 687
BR - Brasile 600
GB - Regno Unito 508
HK - Hong Kong 423
FR - Francia 406
UA - Ucraina 395
CA - Canada 383
VN - Vietnam 373
SE - Svezia 348
FI - Finlandia 257
KR - Corea 184
ZA - Sudafrica 166
TR - Turchia 148
IE - Irlanda 98
IN - India 88
JP - Giappone 87
MX - Messico 58
NL - Olanda 52
AR - Argentina 40
BD - Bangladesh 36
BE - Belgio 36
EU - Europa 33
ES - Italia 30
AT - Austria 25
CZ - Repubblica Ceca 25
EC - Ecuador 22
IQ - Iraq 20
IR - Iran 19
PK - Pakistan 19
ID - Indonesia 17
AE - Emirati Arabi Uniti 16
UZ - Uzbekistan 16
LT - Lituania 15
KE - Kenya 14
VE - Venezuela 14
CO - Colombia 13
AU - Australia 12
CH - Svizzera 12
RO - Romania 12
TW - Taiwan 12
IL - Israele 11
PY - Paraguay 11
SA - Arabia Saudita 11
AZ - Azerbaigian 9
DZ - Algeria 9
JM - Giamaica 9
JO - Giordania 9
EG - Egitto 8
MA - Marocco 8
PH - Filippine 8
RS - Serbia 8
TN - Tunisia 8
CL - Cile 7
PE - Perù 7
HN - Honduras 6
MY - Malesia 6
AL - Albania 5
AM - Armenia 5
BG - Bulgaria 5
CI - Costa d'Avorio 5
DK - Danimarca 5
ET - Etiopia 5
GR - Grecia 5
LB - Libano 5
NP - Nepal 5
TH - Thailandia 5
PA - Panama 4
TT - Trinidad e Tobago 4
BO - Bolivia 3
CR - Costa Rica 3
EE - Estonia 3
HR - Croazia 3
HU - Ungheria 3
KH - Cambogia 3
LV - Lettonia 3
NI - Nicaragua 3
BY - Bielorussia 2
CM - Camerun 2
GE - Georgia 2
GT - Guatemala 2
KW - Kuwait 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MM - Myanmar 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PT - Portogallo 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
Totale 28.039
Salva come PNG Salva come JPEG
Città #
Fairfield 1.294
Ashburn 1.196
Warsaw 1.141
Woodbridge 1.112
Jacksonville 961
Singapore 818
Chandler 762
Houston 706
San Jose 703
Council Bluffs 588
Seattle 577
Wilmington 521
Ann Arbor 481
Cambridge 440
Boardman 418
Hong Kong 401
Beijing 359
Nanjing 318
Dallas 263
Toronto 244
Camerino 227
The Dalles 203
Los Angeles 200
New York 158
Seoul 156
Kraków 152
Johannesburg 151
Columbus 143
San Mateo 143
Tongling 140
Dearborn 137
Princeton 134
Lawrence 133
Helsinki 129
Istanbul 121
Ho Chi Minh City 115
Lauterbourg 113
Ogden 109
Düsseldorf 108
Moscow 106
Nanchang 102
Santa Clara 101
Dublin 97
London 96
Buffalo 93
Hanoi 89
Shanghai 87
Lachine 83
Chicago 75
Guangzhou 69
São Paulo 69
Frankfurt am Main 67
Tokyo 67
Shenyang 66
Milan 63
San Diego 63
Kunming 62
Munich 59
Tianjin 58
Rome 48
Edinburgh 44
St Louis 44
Jiaxing 43
Hebei 42
Orem 42
Centro 39
Brussels 35
Phoenix 35
Atlanta 32
Changsha 30
Ningbo 30
Denver 28
Jinan 28
Manchester 28
Stockholm 28
Trieste 27
Ascoli Piceno 26
Chennai 26
Mexico City 26
Hangzhou 25
Salt Lake City 25
San Francisco 25
Wuhan 25
Montreal 24
Poplar 24
Verona 24
Brooklyn 23
Dong Ket 23
Hefei 23
Boston 22
Norwalk 22
Philadelphia 22
Falls Church 20
Orange 20
Turku 20
Bremen 19
Jinhua 19
Redwood City 19
Rio de Janeiro 19
Tampa 18
Totale 18.789
Salva come PNG Salva come JPEG
Nome #
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 460
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 412
Overview on Radiolabel-Free in Vitro Assays for GPCRs 407
Pharmacological characterization of the GPR17 receptor dual profile 402
GPR17 receptor modulators and their therapeutic implications: review of recent patents 393
The G Protein-Coupled Receptor GPR17: Overview and Update 375
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 368
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 360
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 337
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 301
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 297
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 288
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 281
Levels of polychlorinated biphenyls in fish and shellfish from the Adriatic Sea 273
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 271
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 270
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 265
Biomarkers Mapping in a Neuropathic Pain Mice Model with Sciatic Nerve Chronic Constriction Injury (CCI). 261
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 259
A taxane epoxide from taxus wallichiana 253
3'-Deoxyribofuranose derivatives of 1-deaza and 3-deaza adenosine and their activity as adenosine deaminase inhibitors 252
Adenine and deazaadenine nucleoside and deoxynucleoside analogues: inhibition of viral replication of sheep MVV (in vitro model for HIV) and bovine BHV-1 251
A(2A) adenosine receptor agonists reduce both high-palatability and low-palatability food intake in female rats 250
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines 250
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 250
9-ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities 250
Biomarkers mapping of neuropathic pain in a nerve chronic constriction injury mice model 249
Human cytidine deaminase: understanding the catalytic mechanism 242
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 241
Synthesis and evaluation of hexitol nucleoside congeners as ambiguous nucleosides 240
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 240
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 240
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 238
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs 237
Purine and deazapurine nucleosides: synthetic approaches, molecular modeling and biological activity 235
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 235
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 235
2- And 8- alkynyladenosines: conformational studies and docking to human adenosine A(3) receptor can explain their different biological behavior 228
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 228
Adenosine deaminase: Functional implications and different classes of inhibitors 228
New sensible method to quantize the intestinal absorption of receptor ligands 228
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 224
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 224
Antiviral properties of deazaadenine nucleoside derivatives 223
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 222
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 219
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 215
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 215
Synthesis of a conformationally restricted analogue of paclitaxel 213
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 213
Adenosine receptor modeling: what does the A2A crystal structure tell us? 212
Synthesis and NMR-Driven Conformational Analysis of Taxol Analogues Conformationally Constrained on the C13 Side Chain 210
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site 210
2-substituted 5 '-N-methylcarboxamidoadenosine (MECA) derivatives as A(3) adenosine receptor ligands 209
2- And 8-alkynyl-9-ethyladenines: Synthesis and biological activity at human and rat adenosines receptors 209
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor 209
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family 208
2-phenylhydroxypropynyladenosine derivatives as high potent agonists at A(2B) adenosine receptor subtype 207
Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor. 207
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases 206
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 205
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 204
Ring opening reactions: synthesis of AICAR analogs as potential antimetabolite agents 202
Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists 202
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 201
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 201
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile 200
The Chemistry and Occurrence of Taxane Derivatives. XXVI. A Reactivity Study on 11(15→1)Abeotaxanes 197
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 197
Solid phase synthesis and antiprotozoal evaluation of di- and trisubstituted 5 '-carboxamidoadenosine analogues 196
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 195
Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor 193
GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support 193
A(2B) adenosine receptor agonists: synthesis and biological evaluation of 2-phenylhydroxypropynyladenosine and NECA derivatives 191
[3H]HEMADO – a novel tritiated agonist selective for the human adenosine A(3) receptor 191
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 189
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease 189
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? 189
9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution result in distinct selectivities. 186
Functional cAMP assay optimization at CHO cells expressing A2A adenosine receptors and stably transfected with firefly luciferase biosensor 186
Purine nucleosides bearing 1-alkynyl chains as adenosine receptor agonists 185
Synthesis, structure-affinity relationships and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists 184
Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists 182
N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands 180
Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies 180
Coupling of 2,6-disubstituted purines to ribose-modified sugars 179
Synthesis and stability studies of 2 ',3 ',5 '-tri-O-acetyl-2-amino(-N-6-cyclopentyl)-1-deazaadenosines 179
Synthesis and adenosine receptor affinity and potency of 8-alkynyl derivatives of adenosine 179
Adenine derivatives as inhibitors of the casein kinase CK1delta enzyme 177
Effects of 5 '-phosphate derivatives of 2-hexynyl adenosine and 2-phenylethynyl adenosine on responses of human platelets mediated by P2Y receptors 176
Probing ambiguous base-pairs by genetic transformation with XNA templates 170
Purinergic P2X receptors: Structural models and analysis of receptor-ligand interaction 169
A2A Adenosine Receptor Antagonists and their Potential in Neurological Disorders 169
Highlights on the development of A(2A) adenosine receptor agonists and antagonists 167
Adenosine receptor agonists:synthesis and binding affinity of 2-(aryl)alkylthioadenosine derivatives 164
Adenosine A3 receptor antagonists as anti-tumor treatment in human prostate cancer: an in vitro study 161
N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A(3) adenosine receptor 159
Synthesis of new nucleosides by coupling of chloropurines with 2- and 3-deoxy derivatives of N-methyl-D-ribofuranuronamide 159
Synthesis and biological activity of trisubstituted adenines as A(2A) adenosine receptor antagonists 157
Synthesis, Characterization, and Biological Activity of Purine and Pyrimidine Nucleoside and Nucleotide Analogues 155
Totale 22.973
Salva come PNG Salva come JPEG
Categoria #
all - tutte 116.509
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 116.509
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.463 0 417 34 40 77 81 94 127 125 176 114 178
2022/20231.815 203 122 46 308 177 259 9 106 316 105 111 53
2023/20241.412 190 79 95 63 66 127 55 91 163 38 42 403
2024/20254.798 191 112 389 227 181 291 574 1.190 391 295 307 650
2025/20266.816 426 374 693 956 775 514 1.105 496 410 458 373 236
2026/2027667 488 179 0 0 0 0 0 0 0 0 0 0
Totale 28.471